Focused On-demand Library for CCR4-NOT transcription complex subunit 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

A5YKK6

UPID:

CNOT1_HUMAN

Alternative names:

CCR4-associated factor 1; Negative regulator of transcription subunit 1 homolog

Alternative UPACC:

A5YKK6; Q68DX7; Q7Z3K2; Q8IWB8; Q8TB53; Q9BVZ6; Q9UFR8; Q9UI27; Q9Y2L0

Background:

CCR4-NOT transcription complex subunit 1, also known as CCR4-associated factor 1, plays a pivotal role in mRNA degradation, miRNA-mediated repression, and transcription regulation. It functions as a scaffolding component of the CCR4-NOT complex, influencing mRNA expression through interactions with RNA-binding proteins and the catalytic complex module.

Therapeutic significance:

Linked to Holoprosencephaly 12 and Vissers-Bodmer syndrome, CCR4-NOT transcription complex subunit 1's involvement in these diseases highlights its potential as a target for therapeutic intervention. Understanding its role could open doors to novel treatments for these genetic disorders.